39 related articles for article (PubMed ID: 22805737)
21. Combination antiretroviral therapy and the risk of myocardial infarction.
Friis-Møller N; Sabin CA; Weber R; d'Arminio Monforte A; El-Sadr WM; Reiss P; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Law MG; Kirk O; Phillips AN; Lundgren JD;
N Engl J Med; 2003 Nov; 349(21):1993-2003. PubMed ID: 14627784
[TBL] [Abstract][Full Text] [Related]
22. Acromegaly due to an ectopic pituitary adenoma in the sphenoid sinus.
Gondim JA; Schops M; Ferreira E; Bulcão T; Mota JI; Silveira C
Acta Radiol; 2004 Oct; 45(6):689-91. PubMed ID: 15587430
[TBL] [Abstract][Full Text] [Related]
23. Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Iacob AO; Choudhury RP
Curr Opin Lipidol; 2012 Apr; 23(2):172-4. PubMed ID: 22418577
[No Abstract] [Full Text] [Related]
24. Statins: how far have we come? A review of rosuvastatin.
Olsson A
Int J Clin Pract Suppl; 2003 Oct; (137):15-25. PubMed ID: 14649698
[No Abstract] [Full Text] [Related]
25. Should we measure C-reactive protein on earth or just on JUPITER?
Bajpai A; Goyal A; Sperling L
Clin Cardiol; 2010 Apr; 33(4):190-8. PubMed ID: 20394038
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of rosuvastatin in the management of dyslipidemia.
Rubba P; Marotta G; Gentile M
Vasc Health Risk Manag; 2009; 5(1):343-52. PubMed ID: 19436657
[TBL] [Abstract][Full Text] [Related]
27. New advances in lipid-modifying therapies for reducing cardiovascular risk.
Bruckert E
Cardiology; 2002; 97(2):59-66. PubMed ID: 11978950
[TBL] [Abstract][Full Text] [Related]
28. [Features of the use of rosuvastatin in clinical practice].
Zateĭshchikov DA
Kardiologiia; 2012; 52(11):80-5. PubMed ID: 23237400
[TBL] [Abstract][Full Text] [Related]
29. Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk.
Colotto M; Renzi A; Durante C
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22805737
[TBL] [Abstract][Full Text] [Related]
30. Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory?
de Lorgeril M
World Rev Nutr Diet; 2009; 100():80-89. PubMed ID: 19696530
[No Abstract] [Full Text] [Related]
31. [How to prolong life of patients at high cardiovascular risk. Features of rosuvastatin].
Drapkina OM; Korneeva ON
Kardiologiia; 2012; 52(8):89-92. PubMed ID: 23098406
[No Abstract] [Full Text] [Related]
32. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.
Rizzo M; Rini GB; Berneis K
Adv Ther; 2007; 24(3):575-82. PubMed ID: 17660166
[TBL] [Abstract][Full Text] [Related]
33. Newer pharmaceutical agents to treat lipid disorders.
Davidson MH
Curr Cardiol Rep; 2003 Nov; 5(6):463-9. PubMed ID: 14558988
[TBL] [Abstract][Full Text] [Related]
34. [Acromegaly--do we already know everything about treatment of the somatotroph pituitary adenomas?].
Zieliński G; Podgórski JK
Przegl Lek; 2002; 59(7):540-7. PubMed ID: 12516247
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
